All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 25, 2021
Home » Blogs » BioWorld MedTech Perspectives » Acrimony, acronyms, and life inside the Beltway

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Acrimony, acronyms, and life inside the Beltway

July 10, 2014
By Mark McCarty
No Comments

Abandon all hope ... unless you speak governmentese.
Abandon all hope ... unless you speak governmentese.

It’s that fun time of even-numbered years again when events in Washington bog down with the impending congressional summer recess and the November elections hanging over the heads of nearly everyone in Congress. Despite that Damoclean discomfort, shouldn’t we be rewarded with a regular set of spending bills?

Apparently not.

As best as I can tell, Congress had passed no spending bills for fiscal 2015 on or about July 10, which means we’re almost certainly headed for another series of CRs, or continuing resolutions. The fate of H.R. 4800, the bill that would fund FDA, seems to be that of a paperweight made of – you guessed it – paper. How deliciously ironic.

As matters currently stand, Congress and President Obama are hard at work on a supplemental appropriation for the child migrant predicament. Thankfully the Ryan-Murray budget deal from December of last year puts the sequester on hold for the upcoming fiscal year. Otherwise, device makers would be watching a large amount of user fees going down the nation’s fiscal rabbit hole again.

Alphabet soup; OPPS floats to the surface

If you’re into a mind-bending level of detail, just read through the Medicare outpatient prospective payment system proposal (try saying that three times fast) for calendar year 2015. Not only is it called OPPS by insiders, it talks a lot about CPT and HCPCS (pronounced hick-picks if you’re among the coverage/reimbursement cognoscenti) codes and lots of fun things like that.

CMS posted this and the physician fee proposal July 3 in a vain attempt to ruin everyone’s Fourth of July weekend, but anyone in the cardiology business might want to read through this riveting 600-plus page document. The agency indicated it would like to compress six comprehensive ambulatory payment classification codes (C-APCs) for vascular procedures into three.

Among these are C-APCs 0082 and 0083, which deal with clogged coronary and non-coronary arteries. 0082 is the code for cleaning out the affected artery whereas 0083 applies to angioplasty and valvuloplasty. CMS floated a similar proposal for some electrophysiology codes, squishing another six codes into three, rendering four codes total for levels I through IV for defibrillators, pacemakers and “related devices.”

I won’t pretend to know enough about how this would work in practice to predict whether these proposals would create more headaches than they’d solve, but hospital administrators might think it’s a good thing any time you can reduce the number of codes.

Pronouncing “MPFS” without hurting yourself

What struck me about the Medicare physician fee schedule proposal (MPFS) for calendar 2015 was a discussion about 10- and 90-day global codes for surgical procedures. CMS spent a lot of time explaining the problems with the current set-up, including that the framework was established a couple of decades ago, and OIG has published two reports highlighting the difficulties with these “global” issues. So why tackle it now?

This might be the reason. The continued existence of these codes in their present form may “present obstacles to the adoption of new payment models,” the proposal said.

Not to make too fine a point of it, but the agency might have done the reader a favor and just said up front, “the current set-up stinks and we want to do more bundled payments.” That would have saved me a lot of time.

And while we’re at it … enough already with “next-generation” DNA sequencing. Why is it that every generation of sequencing technology is the next generation? What happened to the current generation?

One supposes I could just be grateful they’re not claiming their technology is “disruptive” anymore.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing